Basic Information
| LncRNA/CircRNA Name | lncARSR |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | RT-qPCR, Western blot |
| Sample | HCC tissues |
| Expression Pattern | up-regulated |
| Function Description | LncARSR was observed to bind to YAP1, which inhibited phosphorylation nuclear translocation. LncARSR activated the IRS2/AKT pathway by reducing YAP1 phosphorylation, and further increased lipid accumulation, cell proliferation, invasion and cell cycle. |
| Pubmed ID | 32169080 |
| Year | 2020 |
| Title | Long noncoding RNA lncARSR promotes nonalcoholic fatty liver disease and?hepatocellular carcinoma by?promoting YAP1 and?activating the?IRS2/AKT pathway |
External Links
| Links for lncARSR | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |